When was D3 Bio founded?

D3 Bio was founded in 2018 and raised its 1st funding round 2 years after it was founded.

Where is D3 Bio located?

D3 Bio is headquartered in Shanghai, China.

Who is the current CEO of D3 Bio?

George Chen of D3 Bio. They have also founded 1 company.

Is D3 Bio a funded company?

D3 Bio is a funded company, having raised a total of $370M across 3 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Nov 17, 2020.

When was the latest funding round of D3 Bio?

D3 Bio's latest funding was a $***** Series B round on Dec 10, 2025, with participation from 6 investors. Its primary sector is Oncology. In China, the Oncology sector has seen $765M in funding in 2026 to date.

Where does D3 Bio rank among its competitors?

D3 Bio ranks 356th amongst 3381 active competitors, of which 1136 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of D3 Bio?

D3 Bio's top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

D3 Bio - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer novel therapeutics for cancer. The company is focusing on developing innovative medicines in oncology and immunology. The company's pipeline include D3S-001 for the treatment of advanced unresectable or metastatic colorectal cancers.

Key Metrics

Founded Year

2018

Location

Shanghai, China

Stage

Series B

Total Funding

$370M in 3 rounds

Latest Funding Round

Series B, Dec 10, 2025, $*****

Investors

Temasek & 9 more

Ranked

356^th among 3381 active competitors

Similar Companies

Jazz Pharmaceuticals & 3051 more

View D3 Bio's full profile

D3 Bio has raised a total funding of $370M over 3 rounds. Its first funding round was on Nov 17, 2020. Its latest funding round was a Series B round on Dec 10, 2025 for $*****. 6 investors participated in its latest round. D3 Bio has 10 institutional investors.

Here is the list of recent funding rounds of D3 Bio:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Dec 10, 2025	6182965	Series B	7856262	3662285	9351380	2574725
Apr 08, 2024	7056434	Series A	3338891	4127712	5131051	WuXi AppTec & 1 more
Nov 17, 2020	4155251	Series A	7974030	1109075	Boyu Capital & 4 more	2669313

Access funding benchmarks and valuations. Sign up today!

View details of D3 Bio's funding rounds and investors

The founders of D3 Bio is George Chen. George Chen is the CEO of D3 Bio.

Here are the details of D3 Bio's key team members:

George Chen: Founder & CEO of D3 Bio.
Contact Info: 1 email address

View details of D3 Bio's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of D3 Bio include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of D3 Bio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, Leaps by Bayer & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
9th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	72/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
356th	D3 Bio 2018, Shanghai (China), Series B	Developer novel therapeutics for cancer	$370M	Temasek, Matrix Partners China & 8 others	56/100